Browse by category

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30% less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Dr Elizabeth McDonald, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing brea

A novel PET imaging framework reveals that bariatric surgery impacts not only body weight, but also the metabolic function of multiple organs. These PET-derived insights into organ-level responses to surgery could support more precise treatment monitoring and personalized metabolic care, according to a study, ‘Evaluation of organic metabolic profiling alternation assessed by [18F]FDG PET/CT in obese patients before and after bariatric surgery’, presented at the Society of Nu

People who undergo bariatric surgery and see substantial weight loss are better able to cope with household tasks such as cleaning, laundry, and grocery shopping. The improvements are also sustained over a long time, according to a study at the University of Gothenburg. The research is based on data from the Swedish Obese Subjects (SOS) study at the University of Gothenburg, the world's most comprehensive study on the long-term effects of bariatric surgery compared to convent

Novo Nordisk has announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy 7.2 mg (once-weekly injectable semaglutide 7.2 mg) in a single-dose pen and Wegovy pill. Wegovy 7.2 mg is already available in the EU for adults with obesity, dosed as three injections of 2.4 mg, and is based on results from the STEP UP trial programme. In the STEP UP

Two studies, led by researchers from the University of Gothenburg, have provided clues to why substantial and sustained weight-loss has been linked to a reduced risk of cancer and cancer-related death, mainly in women. “Our results suggest that there are biological differences between individuals that affect how much cancer risk is reduced after weight loss,” said Dr Kajsa Sjöholm, associate professor at the University of Gothenburg. “By understanding these differences, we wi

Results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes, have revealed that people with severe obesity on the highest dose (12mg) lost on average 30% of their body weight over two years. In addition, at 80 weeks, all doses of retatrutide (4mg, 9mg and 12mg) met the primary and key secondary endpoints for obesity, delivering clinicall

Outcomes from the BARI-STEP trial, led by Dr Janine Makaronidis at the University College London Hospitals (UCLH) Centre for Obesity Research, has concluded that the weight loss drug semaglutide helps patients who do not respond to bariatric surgery. Janine Makaronidis “These findings strengthen the case for using semaglutide in people who do not respond well to bariatric surgery, offering an alternative to repeat operations,” said Makaronidis. “They also suggest that combini

An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid regaining weight, according to a study, ‘Duodenal mucosal resurfacing prevents weight regain after tirzepatide withdrawal: REMAIN-1 multicenter, randomized, double-blind, sham-controlled clinical trial—midpoint cohort results’, presented at Digestive Disease Week 2026. Nearly one in five adults with obesity have taken a glucagon-like peptide-1 (GLP-1), an

The ForePass endoscopic metabolic bypass platform reproduced insulin sensitivity levels observed following biliopancreatic diversion (BPD) while substantially outperforming semaglutide (Ozempic/Wegovy) in weight control in a randomised preclinical study, according to a study led by Professor Ivo Boskoski, Professor of Digestive Endoscopy at Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Rome, Lazio, Italy. ForePass endoscopic metabolic bypass platform

Researchers at Cleveland Clinic have demonstrated that metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis regression can occur following metabolic and bariatric surgery (MBS). The study, “Can Metabolic Surgery Regress MASH Cirrhosis? Evidence From Paired Biopsies,” was presented at the 2026 Digestive Disease Week Annual Meeting. In a retrospective cohort of patients with biopsy-proven compensated MASH cirrhosis undergoing MBS, investigators evaluated long-term